Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for High Risk Hemoglobinopathies
NCT02179359Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2014
- Primary completion
- Nov 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of allogeneic hematopoietic stem cells in sickle cell disease (SCD), thalassemia, Diamond-Blackfan anemia (DBA) and 4 more, sponsored by Masonic Cancer Center. Started Sep 2014; status: terminated.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
sickle cell disease (SCD)thalassemiaDiamond-Blackfan anemia (DBA)paroxysmal nocturnal hemoglobinuria (PNH)Glanzmann thrombasthenia (GT)
Beyond the preview
Go deeper on NCT02179359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179359.